Addressing a pain point in pain research
Tony Oosterveen (left) is a Principal Scientist at bit.bio (Cambridge, UK), a company pioneering the generation of physiologically relevant human cell types from induced pluripotent stem cells (iPSCs) with its deterministic, cell programming opti-ox technology. Tony leads a team focused on developing different neuronal subtypes and glial cells. In this interview from the meeting of the Society for Neuroscience (SfN), Neuroscience 2024 (5–9 October; Chicago, IL, USA), Tony discusses how they used opti-ox to generate nociceptor sensory neurons that respond efficiently to stimuli, providing a potential pain model that could help develop more effective drugs for pain. Could you tell us...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
